FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093166712> ?p ?o ?g. }

• W3093166712 endingPage "114" @default.
• W3093166712 startingPage "100" @default.
• W3093166712 abstract "In pulmonary arterial hypertension (PAH), progressive structural remodeling accounts for the pulmonary vasculopathy including the obliteration of the lung vasculature that causes an increase in vascular resistance and mean blood pressure in the pulmonary arteries ultimately leading to right heart failure-mediated death. Deciphering the molecular details of aberrant signaling of pulmonary vascular cells in PAH is fundamental for the development of new therapeutic strategies. We aimed to identify kinases as new potential drug targets that are dysregulated in PAH by means of a peptide-based kinase activity assay. We performed a tyrosine kinase-dependent phosphorylation assay using 144 selected microarrayed substrate peptides. The differential signature of phosphopeptides was used to predict alterations in tyrosine kinase activities in human pulmonary arterial smooth muscle cells (HPASMCs) from patients with idiopathic PAH (IPAH) compared with healthy control cells. Thereby, we observed an overactivation and an increased expression of Jak2 (Janus kinase 2) in HPASMCs from patients with IPAH as compared with controls. In vitro, IL-6-induced proliferation and migration of HPASMCs from healthy individuals as well as from patients with IPAH were reduced in a dose-dependent manner by the U.S. Food and Drug Administration-approved Jak1 and Jak2 inhibitor ruxolitinib. In vivo, ruxolitinib therapy in two experimental models of pulmonary arterial hypertension dose-dependently attenuated the elevation in pulmonary arterial pressure, partially reduced right ventricular hypertrophy, and almost completely restored cardiac index without signs of adverse events on cardiac function. Therefore, we propose that ruxolitinib may present a novel therapeutic option for patients with PAH by reducing pulmonary vascular remodeling through effectively blocking Jak2-Stat3 (signal transducer of activators of transcription)-mediated signaling pathways." @default.
• W3093166712 created "2020-10-22" @default.
• W3093166712 creator A5004889478 @default.
• W3093166712 creator A5006888214 @default.
• W3093166712 creator A5016511599 @default.
• W3093166712 creator A5027844393 @default.
• W3093166712 creator A5030309692 @default.
• W3093166712 creator A5043026704 @default.
• W3093166712 creator A5052349036 @default.
• W3093166712 creator A5053153176 @default.
• W3093166712 creator A5057524424 @default.
• W3093166712 creator A5068639127 @default.
• W3093166712 creator A5075658674 @default.
• W3093166712 creator A5079163629 @default.
• W3093166712 creator A5086416072 @default.
• W3093166712 date "2021-01-01" @default.
• W3093166712 modified "2023-10-16" @default.
• W3093166712 title "Targeting Jak–Stat Signaling in Experimental Pulmonary Hypertension" @default.
• W3093166712 cites W1835724021 @default.
• W3093166712 cites W1918141746 @default.
• W3093166712 cites W1964727088 @default.
• W3093166712 cites W1967675172 @default.
• W3093166712 cites W1978709703 @default.
• W3093166712 cites W1981214582 @default.
• W3093166712 cites W1982477861 @default.
• W3093166712 cites W1993569315 @default.
• W3093166712 cites W2006232527 @default.
• W3093166712 cites W2011477996 @default.
• W3093166712 cites W2031547741 @default.
• W3093166712 cites W2040599383 @default.
• W3093166712 cites W2054753195 @default.
• W3093166712 cites W2061904133 @default.
• W3093166712 cites W2079645940 @default.
• W3093166712 cites W2098368231 @default.
• W3093166712 cites W2103894337 @default.
• W3093166712 cites W2122401488 @default.
• W3093166712 cites W2128940917 @default.
• W3093166712 cites W2129899732 @default.
• W3093166712 cites W2132001965 @default.
• W3093166712 cites W2132173287 @default.
• W3093166712 cites W2152216118 @default.
• W3093166712 cites W2154059754 @default.
• W3093166712 cites W2161021913 @default.
• W3093166712 cites W2163087340 @default.
• W3093166712 cites W2167283625 @default.
• W3093166712 cites W2222356376 @default.
• W3093166712 cites W2290466312 @default.
• W3093166712 cites W2560056856 @default.
• W3093166712 cites W2563965256 @default.
• W3093166712 cites W2567916801 @default.
• W3093166712 cites W2612868058 @default.
• W3093166712 cites W2758208370 @default.
• W3093166712 cites W2781888165 @default.
• W3093166712 cites W2795700422 @default.
• W3093166712 cites W2796172435 @default.
• W3093166712 cites W2799581227 @default.
• W3093166712 cites W2904157469 @default.
• W3093166712 cites W2904180601 @default.
• W3093166712 cites W2917570538 @default.
• W3093166712 cites W2922208093 @default.
• W3093166712 cites W2945454095 @default.
• W3093166712 cites W2949341266 @default.
• W3093166712 cites W2973599220 @default.
• W3093166712 cites W2998979631 @default.
• W3093166712 cites W3004710819 @default.
• W3093166712 cites W4235569238 @default.
• W3093166712 cites W4241769022 @default.
• W3093166712 cites W848311427 @default.
• W3093166712 doi "https://doi.org/10.1165/rcmb.2019-0431oc" @default.
• W3093166712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33052714" @default.
• W3093166712 hasPublicationYear "2021" @default.
• W3093166712 type Work @default.
• W3093166712 sameAs 3093166712 @default.
• W3093166712 citedByCount "32" @default.
• W3093166712 countsByYear W30931667122021 @default.
• W3093166712 countsByYear W30931667122022 @default.
• W3093166712 countsByYear W30931667122023 @default.
• W3093166712 crossrefType "journal-article" @default.
• W3093166712 hasAuthorship W3093166712A5004889478 @default.
• W3093166712 hasAuthorship W3093166712A5006888214 @default.
• W3093166712 hasAuthorship W3093166712A5016511599 @default.
• W3093166712 hasAuthorship W3093166712A5027844393 @default.
• W3093166712 hasAuthorship W3093166712A5030309692 @default.
• W3093166712 hasAuthorship W3093166712A5043026704 @default.
• W3093166712 hasAuthorship W3093166712A5052349036 @default.
• W3093166712 hasAuthorship W3093166712A5053153176 @default.
• W3093166712 hasAuthorship W3093166712A5057524424 @default.
• W3093166712 hasAuthorship W3093166712A5068639127 @default.
• W3093166712 hasAuthorship W3093166712A5075658674 @default.
• W3093166712 hasAuthorship W3093166712A5079163629 @default.
• W3093166712 hasAuthorship W3093166712A5086416072 @default.
• W3093166712 hasConcept C112392421 @default.
• W3093166712 hasConcept C126322002 @default.
• W3093166712 hasConcept C164705383 @default.
• W3093166712 hasConcept C170493617 @default.
• W3093166712 hasConcept C2776112149 @default.
• W3093166712 hasConcept C2776768464 @default.
• W3093166712 hasConcept C2779376020 @default.

• next